Searchable abstracts of presentations at key conferences in endocrinology

ea0081p220 | Thyroid | ECE2022

Alpelisib-induced thyroiditis in a patient with metastatic breast carcinoma

Prem Kumar Anusha , Flynn Calvin , J Higgins Michaela , K Crowley Rachel , O'Shea Donal , Garrahy Aoife

Background: Alpelisib is a novel phosphotidylinositol 3-kinase (PI3K) inhibitor which, in combination with fulvestrant, has been shown to increase progression-free survival in patients with HR+/HER2-/PI3KCA mutated advanced breast cancer[1]. Hyperglycaemia, including alpelisib-induced diabetic ketoacidosis is a known adverse effect, along with rash, diarrhoea and stomatitis. No other associated endocrinopathy has been reported to date. Case presentation: We present th...